TNFSF13 Antikörper

Produktnummer ABIN7566466

Dieses Maus Monoklonal-Antikörper erkennt spezifisch TNFSF13 in ELISA, IP und Func. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für TNFSF13 Antikörper (ABIN7566466)

Target: TNFSF13 (Tumor Necrosis Factor (Ligand) Superfamily, Member 13 (TNFSF13))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TNFSF13 Antikörper ist unkonjugiert

Applikation: ELISA, Immunoprecipitation (IP), Functional Studies (Func)

Klon: Mahya-1

Produktdetails anti-TNFSF13 Antikörper

Verwendungszweck: anti-APRIL (human), mAb (blocking) (Mahya-1) (preservative free)

Produktmerkmale:

Monoclonal Antibody. Recognizes human APRIL. Does not recognize mouse APRIL or mouse and human BAFF. Applications: ELISA, FUNC (Blocking), IP. Isotype: Mouse IgG1 kappa. Clone: Mahya-1. Liquid. In PBS. The B cell-stimulating molecules, BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand), are critical factors in the maintenance of the B cell pool and humoral immunity. APRIL binds to transmembrane activator and CAML interactor (TACI), B cell maturation antigen (BCMA), and heparan sulfate proteoglycans (HSPG) within the extracellular matrix or on the surface of cells such as plasma cells. APRIL maintains B cell homeostasis by acting at a later stage, modulating the function and survival of antigen-experienced B cells. APRIL (as well as BAFF) stimulates class-switch recombination (CSR), hence contributes to shaping humoral effector mechanisms. With regards to humoral memory, APRIL is involved in the establishment and survival of the long-lived plasma cell (LLPC) pool in the bone marrow (BM). APRIL is expressed by a number of myeloid-derived cell types including BM granulocytes, megakaryocytes, eosinophils and osteoclasts and by dendritic cells following exposure to IFNalpha, IFNgamma or CD40L. APRIL expression is induced during hematopoiesis in the bone marrow. APRIL expression is not limited to cells of myeloid origin, but can also be found in epithelial cells of the gut, tonsil, breast and skin. Finally, APRIL is expressed in tumor cell lines and human cancer cells of colon, thyroid and lymphoid origin. APRIL (a proliferation-inducing ligand) is implicated in several human autoimmune diseases with autoreactive B cell involvement, including systemic lupus erythematosus (SLE), Sjögren's syndrome (SS), IgA nephropathy (IgAN) and rheumatoid arthritis (RA). APRIL might also function in enhancing proliferation of some tumor cells, especially B-cell malignancies.

The B cell-stimulating molecules, BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand), are critical factors in the maintenance of the B cell pool and humoral immunity. APRIL binds to transmembrane activator and CAML interactor (TACI), B cell maturation antigen (BCMA), and heparan sulfate proteoglycans (HSPG) within the extracellular matrix or on the surface of cells such as plasma cells. APRIL maintains B cell homeostasis by acting at a later stage, modulating the function and survival of antigen-experienced B cells. APRIL (as well as BAFF) stimulates class-switch recombination (CSR), hence contributes to shaping humoral effector mechanisms. With regards to humoral memory, APRIL is involved in the establishment and survival of the long-lived plasma cell (LLPC) pool in the bone marrow (BM). APRIL is expressed by a number of myeloid-derived cell types including BM granulocytes, megakaryocytes, eosinophils and osteoclasts and by dendritic cells following exposure to IFN-alpha, IFN-gamma or CD40L. APRIL expression is induced during hematopoiesis in the bone marrow. APRIL expression is not limited to cells of myeloid origin, but can also be found in epithelial cells of the gut, tonsil, breast and skin. Finally, APRIL is expressed in tumor cell lines and human cancer cells of colon, thyroid and lymphoid origin. APRIL (a proliferation-inducing ligand) is implicated in several human autoimmune diseases with autoreactive B cell involvement, including systemic lupus erythematosus (SLE), Sjögren's syndrome (SS), IgA nephropathy (IgAN) and rheumatoid arthritis (RA). APRIL might also function in enhancing proliferation of some tumor cells, especially B cell malignancies.

Aufreinigung: Puified

Reinheit: >95 % (SDS-PAGE)

Endotoxin-Niveau: <0.01EU/μg purified protein (LAL-test, Lonza)

Immunogen: Recombinant human APRIL (aa 98-233).

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: In PBS.

Konservierungsmittel: Without preservative

Handhabung: After opening, prepare aliquots and store at -20 °C.Avoid freeze/thaw cycles.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung:

Stable for at least 1 month after receipt when stored at +4°C.

Stable for at least 1 year after receipt when stored at -20°C.

Details zu TNFSF13

Target: TNFSF13 (Tumor Necrosis Factor (Ligand) Superfamily, Member 13 (TNFSF13))

Andere Bezeichnung: APRIL

UniProt: O75888

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response